Literature DB >> 10100283

High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood.

T Srivastava1, S D Simon, U S Alon.   

Abstract

In recent adult literature, there have been reports of an increasing incidence of focal segmental glomerulosclerosis (FSGS) among patients with nephrotic syndrome. To examine whether this observation is also relevant to the pediatric population we utilized our hospital computerized database to analyze the data on children with primary nephrotic syndrome seen first between the years 1984 and 1995. A questionnaire was also sent to all metropolitan Kansas City pediatricians to identify possible patients outside the database. The inclusion criteria were clinical nephrotic syndrome or proteinuria with a kidney biopsy. A total of 148 patients (group A) were identified; 86 of them from metropolitan Kansas City (group B). In group A the incidence of minimal change disease (MCD) and FSGS was 52.7% [95% confidence interval (CI) 44%-60%] and 23.0% (95% CI 16-29%), respectively and in group B 54.7% (95% CI 44%-65%) and 24.5% (95% CI 15%-33%), respectively. Those numbers were significantly different from the International Study of Kidney Disease in Children (IS-KDC) reported incidence of 76.4% for MCD and 6.9% for FSGS. Similar to the ISKDC, in our population children over 6 years had a higher incidence of FSGS than younger children (32.8% vs. 16.7%, P = 0.028). The annual incidence rate for nephrotic syndrome in group B was 2.2 cases/10(5) children per year, of which MCD comprised 1.22 cases/10(5) children per year and FSGS 0.5 cases/10(5) children per year. The annual incidence rates of both primary nephrotic syndrome (3.6) and FSGS (1.6) were significantly higher in African-Americans, than Caucasians (1.8 and 0.3 cases/10(5) children per year, respectively). Our study indicates nearly no change in the annual incidence of pediatric primary nephrotic syndrome, but a higher incidence of FSGS with reciprocal decline in the incidence of MCD. The possibility of primary nephrotic syndrome being caused by a non-MCD entity is further raised among African-American and in children over 6 years. We conclude that our perception of primary nephrotic syndrome of childhood as a benign condition has to be carefully reexamined and a more-guarded prognostic approach adopted in our geographic area.

Entities:  

Mesh:

Year:  1999        PMID: 10100283     DOI: 10.1007/s004670050555

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  73 in total

1.  Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation.

Authors:  Valérie Leroy; Véronique Fremeaux-Bacchi; Michel Peuchmaur; Véronique Baudouin; Georges Deschênes; Marie-Alice Macher; Chantal Loirat
Journal:  Pediatr Nephrol       Date:  2010-12-25       Impact factor: 3.714

2.  Toll-like receptor 3 (TLR-3), TLR-4 and CD80 expression in peripheral blood mononuclear cells and urinary CD80 levels in children with idiopathic nephrotic syndrome.

Authors:  Om P Mishra; Ravindra Kumar; Gopeshwar Narayan; Pradeep Srivastava; Abhishek Abhinay; Rajniti Prasad; Ankur Singh; Vineeta V Batra
Journal:  Pediatr Nephrol       Date:  2017-02-16       Impact factor: 3.714

3.  Urine proteomic profiling of pediatric nephrotic syndrome.

Authors:  Mona Khurana; Avram Z Traum; Manuel Aivado; Meghan P Wells; Manuel Guerrero; Franck Grall; Towia A Libermann; Asher D Schachter
Journal:  Pediatr Nephrol       Date:  2006-06-30       Impact factor: 3.714

4.  Evolving Epidemiology of Pediatric Glomerular Disease.

Authors:  Michelle N Rheault; Scott E Wenderfer
Journal:  Clin J Am Soc Nephrol       Date:  2018-06-18       Impact factor: 8.237

5.  Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort.

Authors:  Agnes Trautmann; Monica Bodria; Fatih Ozaltin; Alaleh Gheisari; Anette Melk; Marta Azocar; Ali Anarat; Salim Caliskan; Francesco Emma; Jutta Gellermann; Jun Oh; Esra Baskin; Joanna Ksiazek; Giuseppe Remuzzi; Ozlem Erdogan; Sema Akman; Jiri Dusek; Tinatin Davitaia; Ozan Özkaya; Fotios Papachristou; Agnieszka Firszt-Adamczyk; Tomasz Urasinski; Sara Testa; Rafael T Krmar; Lidia Hyla-Klekot; Andrea Pasini; Z Birsin Özcakar; Peter Sallay; Nilgun Cakar; Monica Galanti; Joelle Terzic; Bilal Aoun; Alberto Caldas Afonso; Hanna Szymanik-Grzelak; Beata S Lipska; Sven Schnaidt; Franz Schaefer
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-29       Impact factor: 8.237

6.  Pathological profile of biopsied Egyptian children with primary nephrotic syndrome: 15-year single center experience.

Authors:  Ashraf Bakr; Riham Eid; Amr Sarhan; Ayman Hammad; Ahmed Mahmoud El-Refaey; Atef El-Mougy; Mohammed Magdy Zedan; Fatma Moustafa; Ashraf Abdelrahman
Journal:  J Nephrol       Date:  2014-01-16       Impact factor: 3.902

7.  Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome.

Authors:  Zhihui Li; Cuirong Duan; Jinhua He; Tianhui Wu; Mai Xun; Yi Zhang; Yan Yin
Journal:  Pediatr Nephrol       Date:  2009-12-02       Impact factor: 3.714

8.  Complete remission of nephrotic syndrome in an infant with focal segmental glomerulosclerosis: is it renin-angiotensin blockade?

Authors:  Neveen A Soliman; Magdi Francis; Saskia F Heeringa; Gil Chernin
Journal:  Pediatr Nephrol       Date:  2008-10-14       Impact factor: 3.714

Review 9.  Molecular genetic analysis of podocyte genes in focal segmental glomerulosclerosis--a review.

Authors:  M M Löwik; P J Groenen; E N Levtchenko; L A Monnens; L P van den Heuvel
Journal:  Eur J Pediatr       Date:  2009-06-27       Impact factor: 3.183

10.  Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome.

Authors:  Valderez Raposo de Mello; Maira Tinte Rodrigues; Tais Helena Mastrocinque; Simone Paiva Laranjo Martins; Olberes Vitor Braga de Andrade; Eliana Biondi Medeiros Guidoni; Daniel Kashiwamura Scheffer; Dino Martini Filho; Julio Toporovski; Vanda Benini
Journal:  Pediatr Nephrol       Date:  2010-03       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.